Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir both suppresses virus propagation and modulates the expression of inflammatory cytokines and is used as an anti-influenza virus agent [3]. Umifenovir could effectively inhibit the fusion of virus with host cells [1] [2]. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro [2].
Description | Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir both suppresses virus propagation and modulates the expression of inflammatory cytokines and is used as an anti-influenza virus agent [3]. Umifenovir could effectively inhibit the fusion of virus with host cells [1] [2]. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro [2]. |
In vitro | Umifenovir exhibits broad and potent antiviral effects, demonstrating efficacy against an array of viruses such as influenza types A, B, and C, respiratory syncytial virus, SARS-CoV, adenovirus, parainfluenza type 5, poliovirus 1, rhinovirus 14, coxsackievirus B5, hantaan virus, Chikungunya virus, HBV, and HCV [1]. |
In vivo | Umifenovir, administered orally at doses of 25 and 45 mg/kg/day, demonstrated a survival advantage in BALB/c mice aged 6–8 weeks, inflicted with influenza. The mice were exposed intranasally to a dose twice the 50% lethal dose for mice (2xMLD50) of the A/Guangdong/GIRD07/09 (H1N1) strain, amounting to 10^4.5 TCID50/mL in a 20mL volume. The treatment commenced one day before infection and continued for three days post-infection. Results indicated that at a concentration of 45 mg/mL, Umifenovir significantly increased survival rates and halted the reduction of body weight observed in the virus group. Additionally, at doses of 25 mg/mL and 45 mg/mL, it effectively prevented the escalation of the lung index in mice, thereby showing its potency in mitigating the severity of influenza infections. |
Molecular Weight | 477.41 |
Formula | C22H25BrN2O3S |
CAS No. | 131707-25-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Arbidol 131707-25-0 inhibitor inhibit